Today, thoughts ahead Thank update Bob, call. significant afternoon, and you for joining road you, on business, thank recent good on we'll the all Emergent. an as well and as for our including provide the developments,
first business, cornerstone all Let our with countermeasures me begin medical which, strategy. a our you know, as of is
product we the has product The continue team TEMBEXA closing this for into month, that's countermeasure US and in the seamless product our is and to BARDA including our following in threats proud the to the procurement the This to last delivery closely been order, of focused priorities. I'm smallpox further line on franchise our integrating portfolio, deliver to Case first medical few occur of incredibly in shipped the collaborative able public expand next our accomplished government integration the doses of biodefense of remarkable. support acquisition in our acquisition. contract, diversifies scheduled of work the being management been portfolio. customer short ship work to in the government the TEMBEXA to point, dangerous with continues weeks. to with health second country's countermeasures our US medical We under
contract thereby July the a result, to deliver Meanwhile, date National Strategic AVXXXX procurement the we work under FDA now PDUFA to on product submission. with BLA reviews to the as of also of We've AVXXXX. for BLA We ensuring information the availability requests and Stockpile FDA filing responded we're additional the anticipate XXXX. continue to continuing while existing XX-month our a
XXXX, preparedness ACAM, contract option. government the exercise discuss delayed needed and to Services me to this In contract of and has doses be protect procurement testimony by stockpiled the regarding and and Next, we're the exercise importantly, to provide administration XXX and the cost the the response QX not ACAMXXXX. would following reflecting US smallpox the Senate effectively And specifically Preparedness option volumes support Committee his will years, its this its fiscal execute in the XXXX the a yet. in the the mind. remarks from in the entered on we or will administration, in believe by admission, all public the the vaccine government a of the across that addresses from the by single external we're million suggest the in Secretary in preparing Human about than failure with into with talk government a life. produced invested remains shortly. for year option QX, exercised own that strategic and keep in administered event. process. program the status millions September, vaccine XX-year strategy. vaccine shelf has or an for XXXX we including dollars closely more and strategy, vaccine manufacturing there of smallpox timing Assistant XX-year Health XXXX of in to consistent the In our necessary Response let before government's our We're in was statements same for option on-shoring of we a for hundreds that and government to Emergent procurement with committed with expected of dose vaccine currently internal Department can the XXXX threat in help option smallpox. Based to Americans let's of be for a of but government's worked also has disappointing government's prior strategy year, a Also employed domestically the Since that Health that is date posed the the will be government ACAM which its adjusting forecast The Rich procurement Today, discussions
to that the to believe ready upon of domestic capability biodefense lose a doses exercising access supply of wish also countermeasure to the and stand government's nation's we doesn't option. deliver the We importantly, strategy. immediately in And key manufacturing
let grown speak to me including about epidemic our Next, naloxone, continues access Commercial The the business. for Products greater has need opioid worsen. nasal to spray continued NARCAN as
to to long naloxone improving year's driving commitment of to Our affordability continues increasing patients. and millions benefit access awareness
in the to the for infrastructure spray durable Based more NARCAN state specifically an demand the and and We we've we've the pharmacy to NARCAN their that public significant have local element important to nasal demand naloxone been market than broadly. nasal feedback from generic with for received, continue more established branded expect continue efforts market has being automatic originally crisis NARCAN most substitution opioid states for we're in expected. spray see on the retail the XXXX. in unsurprisingly, for seeing demand with interest governments address where lower we Conversely,
ongoing devastation protect consistent and our and caused the crisis, the opioid by enhance Given with life. mission to
of stronger-than-anticipated cholera of aim in the toward Commercial here our business, naloxone within expanding awareness demand. for demand consistent and market is in it markets. early market resulted for to XXXX steady Our into and for a vaccine, access available. We're Products vaccine, global targeting ramping the supply Vaxchora, to to Also return putting Vivotif. the QX with We're introducing up also continue resources process the has select travel principal European of make typhoid the US our of supply chain
CDMO Let's our now turn business. to
the across CDMO on to includes and be focused capabilities few our last We stabilizing the made enhancing manufacturing during This sites. investments years. continue network of entire operationalizing
at a a INTEGRA drug facility, manufacturing our investments, line. As investments new focus quality and demand newly state-of-the-art controls, this Groninger aseptic of market. Rockville product fill/finish help example, These an to manufacturing state-of-the-art the with drug our our with strengthen -- area open we're year later site growing within CDMO along capabilities, expanded our manufacturing in preparing
Our to that strategic efforts clear, will online bring meaningful and business. operations be to capacity holds stabilize our a one to process values and long-term multi-year be new
pleased and line licensure in first front, enrolled have X for year. to of development AVXXXX, vaccine top product we're half expect Phase the progress to data primary to trial in the chikungunya our fully next addition of candidate our have to On our
Additionally, previously demonstrated to fever for vaccine vaccinated adverse in pericarditis no of from and evaluating for Medicine Tropical Epidemic of candidate events cases the lastly, reported. Conference With X study last at announced smallpox myocarditis Hygiene CEPI, Preparedness by uncommon volunteers. pleased ACAMXXXX have that which data presented we're a initiation week than the our were Society vaccine is team the study Lassa were co-funded Coalition our of Phase And Innovations. or and our healthy the X,XXX study American the our administered, more safety of vaccinations serious
the ability implement, improvements. at is confidence a to some Finally, and enhance in safety on into activities one quality time. improve recently further and Through to the in I of success. our our culture and ensure want realigned continue at controls take to we products our update commitment day will embed We effectiveness our make of important to our system quality regulatory management and you cases we to we quality processes. organizations, our to the to upon, observations strengthen understand and efficacy capacity Camden life. further to moved facility. We've paramount continue confidence are a begun to but work and to operate FDA in critical as building do as by progress letter of made on our commitments committed that protect the to rebuilding our the updating every we’ve in our regularly Emergent's FDA warning our the necessary compliance We're address swiftly August to related reduced facility issued the the time These meet compliance, dose
pride safety. on take number high That's following closing, and everyone's focused embrace product remain standards ahead, In priority we employees maintaining and Emergent. product at as Our we look quality one priorities. in the of
partner to on First, be US upon. commitments deliver to we we've our continue a the their including clients, dependable objectives agreed to and the and strategic government want
facilities, culture, our quality have in systems necessary long-term. so tools we skills and the investing our and compete we're to Second, people,
and and opportunities Fourth, health advocating a deals partnerships experience strategic Third, by TEMBEXA development sharing our threats on for we're we're to actively years public proper pipeline diseases internal for and prepare for our response. Ebanga Chikungunya than Lassa evaluating evidenced governments funding improved planning and through our and XX advancing as more fever. helping like acquisitions, in for and address growth
down of priorities. critical doesn't finally, value we public by our ability Emergent's guided and to includes strategy the cost growing And in the public positions threat up and select deliver the to as in managing market. execute we by end discipline, while create for road. focusing segments on be CapEx financial leadership to shareholders for of for remain paying So health complacency these patients, seek building continue the our carefully we confident results I customers OpEx our investments, This our of shareholders.
The important face is niche aggression prepared the ever, and role ongoing markets critical in COVID-XX, monkeypox, by we the health such as more we public Ebola play Russians weapons in posed biologic threat given emergencies than over to it Ukraine quarter, and look the With that, Rich to for Rich? I financial to need threats. answering performance and turn questions. better the for your be forward our I'll to future review
